𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease

✍ Scribed by L.-M. SHAO; M.-Y. CHEN; Q.-Y. CHEN; J.-T. CAI

Book ID
108605556
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
125 KB
Volume
29
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of certolizumab pego
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
✍ Alain M. Schoepfer; Stephan R. Vavricka; Janek Binek; Christian Felley; Martin G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Background: Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based

Efficacy and safety of certolizumab pego
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
✍ Stephan R. Vavricka; Alain M. Schoepfer; Georg Bansky; Janek Binek; Christian Fe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Background: Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based